Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
45,497
archived clinical trials in
Breast Cancer

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
An Observational Cohort Study of Treatment Patterns and Outcomes in Patients With HER2 Positive (HER2+) Metastatic Breast Cancer (SystHERs Registry (Systemic Therapies for HER2+ Metastatic Breast Cancer Study)).
Status: Enrolling
Updated:  12/31/1969
Texas Oncology - El Paso Cancer Treatment Center Gateway
mi
from
El Paso, TX
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
An Observational Cohort Study of Treatment Patterns and Outcomes in Patients With HER2 Positive (HER2+) Metastatic Breast Cancer (SystHERs Registry (Systemic Therapies for HER2+ Metastatic Breast Cancer Study)).
Status: Enrolling
Updated: 12/31/1969
Texas Oncology - El Paso Cancer Treatment Center Gateway
mi
from
El Paso, TX
Click here to add this to my saved trials
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
An Observational Cohort Study of Treatment Patterns and Outcomes in Patients With HER2 Positive (HER2+) Metastatic Breast Cancer (SystHERs Registry (Systemic Therapies for HER2+ Metastatic Breast Cancer Study)).
Status: Enrolling
Updated:  12/31/1969
Texas Oncology - Fort Worth
mi
from
Fort Worth, TX
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
An Observational Cohort Study of Treatment Patterns and Outcomes in Patients With HER2 Positive (HER2+) Metastatic Breast Cancer (SystHERs Registry (Systemic Therapies for HER2+ Metastatic Breast Cancer Study)).
Status: Enrolling
Updated: 12/31/1969
Texas Oncology - Fort Worth
mi
from
Fort Worth, TX
Click here to add this to my saved trials
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
An Observational Cohort Study of Treatment Patterns and Outcomes in Patients With HER2 Positive (HER2+) Metastatic Breast Cancer (SystHERs Registry (Systemic Therapies for HER2+ Metastatic Breast Cancer Study)).
Status: Enrolling
Updated:  12/31/1969
Texas Oncology - Houston (Gessner)
mi
from
Houston, TX
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
An Observational Cohort Study of Treatment Patterns and Outcomes in Patients With HER2 Positive (HER2+) Metastatic Breast Cancer (SystHERs Registry (Systemic Therapies for HER2+ Metastatic Breast Cancer Study)).
Status: Enrolling
Updated: 12/31/1969
Texas Oncology - Houston (Gessner)
mi
from
Houston, TX
Click here to add this to my saved trials
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
An Observational Cohort Study of Treatment Patterns and Outcomes in Patients With HER2 Positive (HER2+) Metastatic Breast Cancer (SystHERs Registry (Systemic Therapies for HER2+ Metastatic Breast Cancer Study)).
Status: Enrolling
Updated:  12/31/1969
Texas Oncology, P.A. - McAllen; South Texas Cancer Center-McAllen
mi
from
McAllen, TX
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
An Observational Cohort Study of Treatment Patterns and Outcomes in Patients With HER2 Positive (HER2+) Metastatic Breast Cancer (SystHERs Registry (Systemic Therapies for HER2+ Metastatic Breast Cancer Study)).
Status: Enrolling
Updated: 12/31/1969
Texas Oncology, P.A. - McAllen; South Texas Cancer Center-McAllen
mi
from
McAllen, TX
Click here to add this to my saved trials
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
An Observational Cohort Study of Treatment Patterns and Outcomes in Patients With HER2 Positive (HER2+) Metastatic Breast Cancer (SystHERs Registry (Systemic Therapies for HER2+ Metastatic Breast Cancer Study)).
Status: Enrolling
Updated:  12/31/1969
Texas Oncology-Paris
mi
from
Paris, TX
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
An Observational Cohort Study of Treatment Patterns and Outcomes in Patients With HER2 Positive (HER2+) Metastatic Breast Cancer (SystHERs Registry (Systemic Therapies for HER2+ Metastatic Breast Cancer Study)).
Status: Enrolling
Updated: 12/31/1969
Texas Oncology-Paris
mi
from
Paris, TX
Click here to add this to my saved trials
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
An Observational Cohort Study of Treatment Patterns and Outcomes in Patients With HER2 Positive (HER2+) Metastatic Breast Cancer (SystHERs Registry (Systemic Therapies for HER2+ Metastatic Breast Cancer Study)).
Status: Enrolling
Updated:  12/31/1969
Tyler Hematololgy Oncology, PA
mi
from
Tyler, TX
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
An Observational Cohort Study of Treatment Patterns and Outcomes in Patients With HER2 Positive (HER2+) Metastatic Breast Cancer (SystHERs Registry (Systemic Therapies for HER2+ Metastatic Breast Cancer Study)).
Status: Enrolling
Updated: 12/31/1969
Tyler Hematololgy Oncology, PA
mi
from
Tyler, TX
Click here to add this to my saved trials
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
An Observational Cohort Study of Treatment Patterns and Outcomes in Patients With HER2 Positive (HER2+) Metastatic Breast Cancer (SystHERs Registry (Systemic Therapies for HER2+ Metastatic Breast Cancer Study)).
Status: Enrolling
Updated:  12/31/1969
Texas Oncology
mi
from
Waco, TX
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
An Observational Cohort Study of Treatment Patterns and Outcomes in Patients With HER2 Positive (HER2+) Metastatic Breast Cancer (SystHERs Registry (Systemic Therapies for HER2+ Metastatic Breast Cancer Study)).
Status: Enrolling
Updated: 12/31/1969
Texas Oncology
mi
from
Waco, TX
Click here to add this to my saved trials
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
An Observational Cohort Study of Treatment Patterns and Outcomes in Patients With HER2 Positive (HER2+) Metastatic Breast Cancer (SystHERs Registry (Systemic Therapies for HER2+ Metastatic Breast Cancer Study)).
Status: Enrolling
Updated:  12/31/1969
Texas Oncology, P.A.; Duke Slayton Cancer Center
mi
from
Webster, TX
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
An Observational Cohort Study of Treatment Patterns and Outcomes in Patients With HER2 Positive (HER2+) Metastatic Breast Cancer (SystHERs Registry (Systemic Therapies for HER2+ Metastatic Breast Cancer Study)).
Status: Enrolling
Updated: 12/31/1969
Texas Oncology, P.A.; Duke Slayton Cancer Center
mi
from
Webster, TX
Click here to add this to my saved trials
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
An Observational Cohort Study of Treatment Patterns and Outcomes in Patients With HER2 Positive (HER2+) Metastatic Breast Cancer (SystHERs Registry (Systemic Therapies for HER2+ Metastatic Breast Cancer Study)).
Status: Enrolling
Updated:  12/31/1969
Northern Utah Associates
mi
from
Ogden, UT
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
An Observational Cohort Study of Treatment Patterns and Outcomes in Patients With HER2 Positive (HER2+) Metastatic Breast Cancer (SystHERs Registry (Systemic Therapies for HER2+ Metastatic Breast Cancer Study)).
Status: Enrolling
Updated: 12/31/1969
Northern Utah Associates
mi
from
Ogden, UT
Click here to add this to my saved trials
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
An Observational Cohort Study of Treatment Patterns and Outcomes in Patients With HER2 Positive (HER2+) Metastatic Breast Cancer (SystHERs Registry (Systemic Therapies for HER2+ Metastatic Breast Cancer Study)).
Status: Enrolling
Updated:  12/31/1969
Huntsman Cancer Institute; Oncology
mi
from
Salt Lake City, UT
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
An Observational Cohort Study of Treatment Patterns and Outcomes in Patients With HER2 Positive (HER2+) Metastatic Breast Cancer (SystHERs Registry (Systemic Therapies for HER2+ Metastatic Breast Cancer Study)).
Status: Enrolling
Updated: 12/31/1969
Huntsman Cancer Institute; Oncology
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
An Observational Cohort Study of Treatment Patterns and Outcomes in Patients With HER2 Positive (HER2+) Metastatic Breast Cancer (SystHERs Registry (Systemic Therapies for HER2+ Metastatic Breast Cancer Study)).
Status: Enrolling
Updated:  12/31/1969
Lynchburg Hem Onc Clinic Inc
mi
from
Lynchburg, VA
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
An Observational Cohort Study of Treatment Patterns and Outcomes in Patients With HER2 Positive (HER2+) Metastatic Breast Cancer (SystHERs Registry (Systemic Therapies for HER2+ Metastatic Breast Cancer Study)).
Status: Enrolling
Updated: 12/31/1969
Lynchburg Hem Onc Clinic Inc
mi
from
Lynchburg, VA
Click here to add this to my saved trials
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
An Observational Cohort Study of Treatment Patterns and Outcomes in Patients With HER2 Positive (HER2+) Metastatic Breast Cancer (SystHERs Registry (Systemic Therapies for HER2+ Metastatic Breast Cancer Study)).
Status: Enrolling
Updated:  12/31/1969
Peninsula Cancer Institute
mi
from
Newport News, VA
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
An Observational Cohort Study of Treatment Patterns and Outcomes in Patients With HER2 Positive (HER2+) Metastatic Breast Cancer (SystHERs Registry (Systemic Therapies for HER2+ Metastatic Breast Cancer Study)).
Status: Enrolling
Updated: 12/31/1969
Peninsula Cancer Institute
mi
from
Newport News, VA
Click here to add this to my saved trials
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
An Observational Cohort Study of Treatment Patterns and Outcomes in Patients With HER2 Positive (HER2+) Metastatic Breast Cancer (SystHERs Registry (Systemic Therapies for HER2+ Metastatic Breast Cancer Study)).
Status: Enrolling
Updated:  12/31/1969
Virginia Cancer Institute
mi
from
Richmond, VA
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
An Observational Cohort Study of Treatment Patterns and Outcomes in Patients With HER2 Positive (HER2+) Metastatic Breast Cancer (SystHERs Registry (Systemic Therapies for HER2+ Metastatic Breast Cancer Study)).
Status: Enrolling
Updated: 12/31/1969
Virginia Cancer Institute
mi
from
Richmond, VA
Click here to add this to my saved trials
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
An Observational Cohort Study of Treatment Patterns and Outcomes in Patients With HER2 Positive (HER2+) Metastatic Breast Cancer (SystHERs Registry (Systemic Therapies for HER2+ Metastatic Breast Cancer Study)).
Status: Enrolling
Updated:  12/31/1969
Shenandoah Oncology Associates, PC
mi
from
Winchester, VA
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
An Observational Cohort Study of Treatment Patterns and Outcomes in Patients With HER2 Positive (HER2+) Metastatic Breast Cancer (SystHERs Registry (Systemic Therapies for HER2+ Metastatic Breast Cancer Study)).
Status: Enrolling
Updated: 12/31/1969
Shenandoah Oncology Associates, PC
mi
from
Winchester, VA
Click here to add this to my saved trials
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
An Observational Cohort Study of Treatment Patterns and Outcomes in Patients With HER2 Positive (HER2+) Metastatic Breast Cancer (SystHERs Registry (Systemic Therapies for HER2+ Metastatic Breast Cancer Study)).
Status: Enrolling
Updated:  12/31/1969
Virginia Mason Medical Center
mi
from
Seattle, WA
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
An Observational Cohort Study of Treatment Patterns and Outcomes in Patients With HER2 Positive (HER2+) Metastatic Breast Cancer (SystHERs Registry (Systemic Therapies for HER2+ Metastatic Breast Cancer Study)).
Status: Enrolling
Updated: 12/31/1969
Virginia Mason Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
An Observational Cohort Study of Treatment Patterns and Outcomes in Patients With HER2 Positive (HER2+) Metastatic Breast Cancer (SystHERs Registry (Systemic Therapies for HER2+ Metastatic Breast Cancer Study)).
Status: Enrolling
Updated:  12/31/1969
West Virginia University Hospitals Inc.
mi
from
Morgantown, WV
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
An Observational Cohort Study of Treatment Patterns and Outcomes in Patients With HER2 Positive (HER2+) Metastatic Breast Cancer (SystHERs Registry (Systemic Therapies for HER2+ Metastatic Breast Cancer Study)).
Status: Enrolling
Updated: 12/31/1969
West Virginia University Hospitals Inc.
mi
from
Morgantown, WV
Click here to add this to my saved trials
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
An Observational Cohort Study of Treatment Patterns and Outcomes in Patients With HER2 Positive (HER2+) Metastatic Breast Cancer (SystHERs Registry (Systemic Therapies for HER2+ Metastatic Breast Cancer Study)).
Status: Enrolling
Updated:  12/31/1969
University of Wisconsin
mi
from
Madison, WI
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
An Observational Cohort Study of Treatment Patterns and Outcomes in Patients With HER2 Positive (HER2+) Metastatic Breast Cancer (SystHERs Registry (Systemic Therapies for HER2+ Metastatic Breast Cancer Study)).
Status: Enrolling
Updated: 12/31/1969
University of Wisconsin
mi
from
Madison, WI
Click here to add this to my saved trials
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
An Observational Cohort Study of Treatment Patterns and Outcomes in Patients With HER2 Positive (HER2+) Metastatic Breast Cancer (SystHERs Registry (Systemic Therapies for HER2+ Metastatic Breast Cancer Study)).
Status: Enrolling
Updated:  12/31/1969
Columbia Saint Mary's; Medical Oncology
mi
from
Milwaukee, WI
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
An Observational Cohort Study of Treatment Patterns and Outcomes in Patients With HER2 Positive (HER2+) Metastatic Breast Cancer (SystHERs Registry (Systemic Therapies for HER2+ Metastatic Breast Cancer Study)).
Status: Enrolling
Updated: 12/31/1969
Columbia Saint Mary's; Medical Oncology
mi
from
Milwaukee, WI
Click here to add this to my saved trials
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
An Observational Cohort Study of Treatment Patterns and Outcomes in Patients With HER2 Positive (HER2+) Metastatic Breast Cancer (SystHERs Registry (Systemic Therapies for HER2+ Metastatic Breast Cancer Study)).
Status: Enrolling
Updated:  12/31/1969
Central Coast Medical Oncology
mi
from
Santa Maria, CA
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
An Observational Cohort Study of Treatment Patterns and Outcomes in Patients With HER2 Positive (HER2+) Metastatic Breast Cancer (SystHERs Registry (Systemic Therapies for HER2+ Metastatic Breast Cancer Study)).
Status: Enrolling
Updated: 12/31/1969
Central Coast Medical Oncology
mi
from
Santa Maria, CA
Click here to add this to my saved trials
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
An Observational Cohort Study of Treatment Patterns and Outcomes in Patients With HER2 Positive (HER2+) Metastatic Breast Cancer (SystHERs Registry (Systemic Therapies for HER2+ Metastatic Breast Cancer Study)).
Status: Enrolling
Updated:  12/31/1969
Baptist MD Anderson Cancer Center
mi
from
Jacksonville, FL
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
An Observational Cohort Study of Treatment Patterns and Outcomes in Patients With HER2 Positive (HER2+) Metastatic Breast Cancer (SystHERs Registry (Systemic Therapies for HER2+ Metastatic Breast Cancer Study)).
Status: Enrolling
Updated: 12/31/1969
Baptist MD Anderson Cancer Center
mi
from
Jacksonville, FL
Click here to add this to my saved trials
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
An Observational Cohort Study of Treatment Patterns and Outcomes in Patients With HER2 Positive (HER2+) Metastatic Breast Cancer (SystHERs Registry (Systemic Therapies for HER2+ Metastatic Breast Cancer Study)).
Status: Enrolling
Updated:  12/31/1969
Berkshire Hematology Oncology, PC
mi
from
Pittsfield, MA
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
An Observational Cohort Study of Treatment Patterns and Outcomes in Patients With HER2 Positive (HER2+) Metastatic Breast Cancer (SystHERs Registry (Systemic Therapies for HER2+ Metastatic Breast Cancer Study)).
Status: Enrolling
Updated: 12/31/1969
Berkshire Hematology Oncology, PC
mi
from
Pittsfield, MA
Click here to add this to my saved trials
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
An Observational Cohort Study of Treatment Patterns and Outcomes in Patients With HER2 Positive (HER2+) Metastatic Breast Cancer (SystHERs Registry (Systemic Therapies for HER2+ Metastatic Breast Cancer Study)).
Status: Enrolling
Updated:  12/31/1969
Park Nicollet Clinic Cancer Center
mi
from
Saint Louis Park, MN
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
An Observational Cohort Study of Treatment Patterns and Outcomes in Patients With HER2 Positive (HER2+) Metastatic Breast Cancer (SystHERs Registry (Systemic Therapies for HER2+ Metastatic Breast Cancer Study)).
Status: Enrolling
Updated: 12/31/1969
Park Nicollet Clinic Cancer Center
mi
from
Saint Louis Park, MN
Click here to add this to my saved trials
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
An Observational Cohort Study of Treatment Patterns and Outcomes in Patients With HER2 Positive (HER2+) Metastatic Breast Cancer (SystHERs Registry (Systemic Therapies for HER2+ Metastatic Breast Cancer Study)).
Status: Enrolling
Updated:  12/31/1969
Christian Hospital; Outpatient Cancer and Infusion Center
mi
from
Saint Louis, MO
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
An Observational Cohort Study of Treatment Patterns and Outcomes in Patients With HER2 Positive (HER2+) Metastatic Breast Cancer (SystHERs Registry (Systemic Therapies for HER2+ Metastatic Breast Cancer Study)).
Status: Enrolling
Updated: 12/31/1969
Christian Hospital; Outpatient Cancer and Infusion Center
mi
from
Saint Louis, MO
Click here to add this to my saved trials
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
An Observational Cohort Study of Treatment Patterns and Outcomes in Patients With HER2 Positive (HER2+) Metastatic Breast Cancer (SystHERs Registry (Systemic Therapies for HER2+ Metastatic Breast Cancer Study)).
Status: Enrolling
Updated:  12/31/1969
St. John's Mercy Medical Ctr; David C. Pratt Cancer Center
mi
from
Saint Louis, MO
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
An Observational Cohort Study of Treatment Patterns and Outcomes in Patients With HER2 Positive (HER2+) Metastatic Breast Cancer (SystHERs Registry (Systemic Therapies for HER2+ Metastatic Breast Cancer Study)).
Status: Enrolling
Updated: 12/31/1969
St. John's Mercy Medical Ctr; David C. Pratt Cancer Center
mi
from
Saint Louis, MO
Click here to add this to my saved trials
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
An Observational Cohort Study of Treatment Patterns and Outcomes in Patients With HER2 Positive (HER2+) Metastatic Breast Cancer (SystHERs Registry (Systemic Therapies for HER2+ Metastatic Breast Cancer Study)).
Status: Enrolling
Updated:  12/31/1969
Cancer Alliance of Nebraska
mi
from
Omaha, NE
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
An Observational Cohort Study of Treatment Patterns and Outcomes in Patients With HER2 Positive (HER2+) Metastatic Breast Cancer (SystHERs Registry (Systemic Therapies for HER2+ Metastatic Breast Cancer Study)).
Status: Enrolling
Updated: 12/31/1969
Cancer Alliance of Nebraska
mi
from
Omaha, NE
Click here to add this to my saved trials
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
An Observational Cohort Study of Treatment Patterns and Outcomes in Patients With HER2 Positive (HER2+) Metastatic Breast Cancer (SystHERs Registry (Systemic Therapies for HER2+ Metastatic Breast Cancer Study)).
Status: Enrolling
Updated:  12/31/1969
Mercy Clinic Oklahoma Communties, Inc
mi
from
Oklahoma City, OK
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
An Observational Cohort Study of Treatment Patterns and Outcomes in Patients With HER2 Positive (HER2+) Metastatic Breast Cancer (SystHERs Registry (Systemic Therapies for HER2+ Metastatic Breast Cancer Study)).
Status: Enrolling
Updated: 12/31/1969
Mercy Clinic Oklahoma Communties, Inc
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
An Observational Cohort Study of Treatment Patterns and Outcomes in Patients With HER2 Positive (HER2+) Metastatic Breast Cancer (SystHERs Registry (Systemic Therapies for HER2+ Metastatic Breast Cancer Study)).
Status: Enrolling
Updated:  12/31/1969
MedStar Washington Hospital Center
mi
from
Washington,
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
An Observational Cohort Study of Treatment Patterns and Outcomes in Patients With HER2 Positive (HER2+) Metastatic Breast Cancer (SystHERs Registry (Systemic Therapies for HER2+ Metastatic Breast Cancer Study)).
Status: Enrolling
Updated: 12/31/1969
MedStar Washington Hospital Center
mi
from
Washington,
Click here to add this to my saved trials
Tumor Specific Plasma DNA
Tumor Specific Plasma DNA
Status: Enrolling
Updated:  12/31/1969
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Tumor Specific Plasma DNA
Tumor Specific Plasma DNA
Status: Enrolling
Updated: 12/31/1969
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
Status: Enrolling
Updated:  12/31/1969
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
Status: Enrolling
Updated: 12/31/1969
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
Status: Enrolling
Updated:  12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
Status: Enrolling
Updated:  12/31/1969
M.D. Anderson Cancer Center
mi
from
Houston, TX
Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
Status: Enrolling
Updated: 12/31/1969
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Metabolizing Enzyme Genotype Versus Exemestane Metabolism Profiles
Metabolizing Enzyme Genotype Versus Exemestane Metabolism Profiles
Status: Enrolling
Updated:  12/31/1969
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Metabolizing Enzyme Genotype Versus Exemestane Metabolism Profiles
Metabolizing Enzyme Genotype Versus Exemestane Metabolism Profiles
Status: Enrolling
Updated: 12/31/1969
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
Exemestane-RAD001-Metformin
Circulating FGF21 Levels and Efficacy of Exemestane, Everolimus and Metformin in Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer and BMI >/= 25
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Exemestane-RAD001-Metformin
Circulating FGF21 Levels and Efficacy of Exemestane, Everolimus and Metformin in Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer and BMI >/= 25
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers
Status: Enrolling
Updated:  12/31/1969
Yale University School of Medicine
mi
from
New Haven, CT
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers
Status: Enrolling
Updated: 12/31/1969
Yale University School of Medicine
mi
from
New Haven, CT
Click here to add this to my saved trials
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers
Status: Enrolling
Updated:  12/31/1969
Helen F. Graham Cancer Center
mi
from
Newark, DE
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers
Status: Enrolling
Updated: 12/31/1969
Helen F. Graham Cancer Center
mi
from
Newark, DE
Click here to add this to my saved trials
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers
Status: Enrolling
Updated:  12/31/1969
MD Anderson Cancer Center Orlando (UF Health Cancer Center)
mi
from
Orlando, FL
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers
Status: Enrolling
Updated: 12/31/1969
MD Anderson Cancer Center Orlando (UF Health Cancer Center)
mi
from
Orlando, FL
Click here to add this to my saved trials
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers
Status: Enrolling
Updated:  12/31/1969
IU Health Goshen Cancer Center
mi
from
Goshen, IN
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers
Status: Enrolling
Updated: 12/31/1969
IU Health Goshen Cancer Center
mi
from
Goshen, IN
Click here to add this to my saved trials
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers
Status: Enrolling
Updated:  12/31/1969
Massachusettes General Hospital
mi
from
Boston, MA
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers
Status: Enrolling
Updated: 12/31/1969
Massachusettes General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers
Status: Enrolling
Updated:  12/31/1969
Weill Cornell -New York Presbyterian Hospital
mi
from
New York, NY
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers
Status: Enrolling
Updated: 12/31/1969
Weill Cornell -New York Presbyterian Hospital
mi
from
New York, NY
Click here to add this to my saved trials
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers
Status: Enrolling
Updated:  12/31/1969
Columbia University Herbert Irving Cancer Center
mi
from
New York, NY
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers
Status: Enrolling
Updated: 12/31/1969
Columbia University Herbert Irving Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers
Status: Enrolling
Updated:  12/31/1969
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers
Status: Enrolling
Updated: 12/31/1969
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers
Status: Enrolling
Updated:  12/31/1969
Texas Oncology Sammons Cancer Center
mi
from
Dallas, TX
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers
Status: Enrolling
Updated: 12/31/1969
Texas Oncology Sammons Cancer Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers
Status: Enrolling
Updated:  12/31/1969
Virginia Mason Cancer Center
mi
from
Seattle, WA
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers
Status: Enrolling
Updated: 12/31/1969
Virginia Mason Cancer Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers
Status: Enrolling
Updated:  12/31/1969
Moffitt Cancer Center
mi
from
Tampa, FL
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers
Status: Enrolling
Updated: 12/31/1969
Moffitt Cancer Center
mi
from
Tampa, FL
Click here to add this to my saved trials
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers
Status: Enrolling
Updated:  12/31/1969
University of Colorado Anschutz Medical Campus
mi
from
Aurora, CO
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers
Status: Enrolling
Updated: 12/31/1969
University of Colorado Anschutz Medical Campus
mi
from
Aurora, CO
Click here to add this to my saved trials
Vaccine Therapy in Treating Patients With Previously Treated Stage II-III HER2-Positive Breast Cancer
A Phase I Trial of the Safety and Immunogenicity of a Multi-epitope HER-2/Neu Peptide Vaccine in Subjects Previously Treated for HER-2 Positive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Vaccine Therapy in Treating Patients With Previously Treated Stage II-III HER2-Positive Breast Cancer
A Phase I Trial of the Safety and Immunogenicity of a Multi-epitope HER-2/Neu Peptide Vaccine in Subjects Previously Treated for HER-2 Positive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Feasibility of Delivering a Quitline Based Smoking Cessation Intervention in Cancer Patients
Feasibility of Delivering a Quitline Based Smoking Cessation Intervention in Lung Cancer Patients Receiving Outpatient Treatment: A Pilot Study
Status: Enrolling
Updated:  12/31/1969
W F Baptist Health
mi
from
Winston-Salem, NC
Feasibility of Delivering a Quitline Based Smoking Cessation Intervention in Cancer Patients
Feasibility of Delivering a Quitline Based Smoking Cessation Intervention in Lung Cancer Patients Receiving Outpatient Treatment: A Pilot Study
Status: Enrolling
Updated: 12/31/1969
W F Baptist Health
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Sientra Post-Approval Study
U.S. Postapproval Study of Sientra Silicone Gel Breast Implants
Status: Enrolling
Updated:  12/31/1969
Sientra, Inc.
mi
from
Santa Barbara, CA
Sientra Post-Approval Study
U.S. Postapproval Study of Sientra Silicone Gel Breast Implants
Status: Enrolling
Updated: 12/31/1969
Sientra, Inc.
mi
from
Santa Barbara, CA
Click here to add this to my saved trials